A molecular classification of papillary renal cell carcinoma

Cancer Research

Volumn 65, Issue 13, 2005, Pages 5628-5637

  Yang, Ximing J ^a   Tan, Min Han ^c,h,i   Kim, Hyung L ^e   Ditlev, Jonathon A ^c   Betten, Mark W ^c   Png, Carolina E ^c   Kort, Eric J ^c   Futami, Kunihiko ^c   Furge, Kyle A ^c   Takahashi, Masayuki ^c,f   Kanayama, Hiro Omi ^f   Tan, Puay Hoon ^g   Teh, Bin Sing ^j   Luan, Chunyan ^a   Wang, Kim ^a   Pins, Michael ^a   Tretiakova, Maria ^b   Anema, John ^d   Kahnoski, Richard ^d   Nicol, Theresa ^k   Stadler, Walter ^b   Vogelzang, Nicholas G ^l   Amato, Robert ^j   Seligson, David ^e   Figlin, Robert ^e   Belldegrun, Arie ^e   Rogers, Craig G ^k   Teh, Bin Tean ^c,m   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d SPECTRUM HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TOKUSHIMA   (Japan)

^g SINGAPORE GENERAL HOSPITAL   (Singapore)

^h National Cancer Center

ⁱ ALEXANDRA HOSPITAL   (Singapore)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NEVADA CANCER INSTITUTE   (United States)

^m NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 7; DNA TOPOISOMERASE (ATP HYDROLYSING) A;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC SELECTION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; KIDNEY CARCINOMA; MALE; MOLECULAR GENETICS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 21344446106     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0533     Document Type: Article

References (42)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IAHC Press; 2004.
2. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-9.
3. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
4. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997;21:621-35.
6. Kuroda N, Toi M, Hiroi M, Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003;18:487-94.
7. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-44.
8. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and mulufocality. J Urol 2003;170:764-7.
9. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003:27:612-24.
10. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-91.
11. Motzer RJ, Bacik J, Mariant T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81.
12. Tan MH, Rogers CG, Cooper JT, et al. Gene expression profiling of renal cell carcinoma. Clin Cancer Res 2004;10:6315-21S.
13. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162:925-32.
14. Takahashi M, Rhodes DR, Purge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001;98:9754-9.
15. Takahashi M, Yang XJ, Lavery TT, et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 2002;62:6598-605.
16. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22:6810-8.
17. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
18. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001;11:1861-70.
19. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of α-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 2004;28:69-76.
20. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
22. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
23. Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004;64:4117-21.
24. Jiang Y, Zhang W, Kondo K, et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 2003;1:453-62.
25. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997;28:459-64.
26. Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A. Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virchows Arch 2003;442:336-42.
27. Hughes TR, Roberts CJ, Dai H, et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat Genet 2000;25:333-7.
28. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 1991;3:249-55.
29. Kattar MM, Grignon DJ, Wallis T, et al. Clinicopathologic and interphase cytogenetic analysis of papillary (chromophilic) renal cell carcinoma. Mod Pathol 1997;10:1143-50.
30. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998;153:1467-73.
31. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003;63:6200-5.
32. Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors. Morphologic, cytochemical, and genotypic features. Cancer 1995;76:669-73.
33. Renshaw AA, Corless CL. Papillary renal cell carcinoma. Histology and immunohistochemistry. Am J Surg Pathol 1995;19:842-9.
34. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11.
35. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998;58:1719-22.
36. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
37. Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 2004;101:10608-13.
38. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
39. 2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 2003;63:4074-81.
40. Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 2002;168:959-61.
41. Law TM, Mencel P, Motzer RJ. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:323-5.
42. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.